The popular carotid stent, WALLSTENT® Monorail® Endoprosthesis, from Boston Scientific has been approved for marketing by US regulators. The device, indicated for the treatment of patients with carotid artery disease who are at high risk for surgery, has been on the European market for a few years now. According to its press release, the company plans to launch the product immediately in the United States.
The Carotid WALLSTENT is a self-expanding stent mounted on a rapid exchange delivery system, designed to re-open the carotid artery by treating stenoses, and improve blood flow to the brain. The stent features a closed-cell design, engineered for excellent lesion coverage and angiographic results. The system is designed to be highly deliverable and provide access to the toughest lesions.
It is used in conjunction with the FilterWire EZ™ Embolic Protection System, which is designed to capture plaque debris released during the stenting procedure, preventing it from traveling to the brain, where it could create an increased risk for stroke. The device features simplified filter sizing – accommodating vessel diameters between 3.5 mm and 5.5 mm – and offers efficient preparation, deployment and retrieval.
"The closed-cell design of the Carotid WALLSTENT Endoprosthesis is intended to provide increased scaffolding for optimal lesion coverage and a smooth inner lumen," said Barry T. Katzen, M.D., Medical Director, Baptist Cardiac and Vascular Institute, Miami. "This feature will make the Carotid WALLSTENT an attractive new treatment option for U.S. physicians and their patients."
The Carotid WALLSTENT Endoprosthesis with the FilterWire EZ System is the only carotid artery stent system approved in the United States with an indication that includes the treatment of bilateral carotid artery disease (blockages in the carotid arteries on both sides of the neck).
Product page: WALLSTENT® Monorail® Endoprosthesis…
Press release: FDA Approves Boston Scientific’s Carotid Artery Stent…